Antibiotic resistant bacteria threaten global health. Nevertheless, few new antibiotics have come onto the market in the last 50 years.
Forget TIGIT: Novartis’ $1B bet on BeiGene’s ociperlimab ends after competitors’ setbacks
Novartis and BeiGene have mutually agreed to axe their collaboration on a Phase III TIGIT inhibitor, marking another derailment in a field once thought to
July 12, 2023